| scholarly article | Q13442814 |
| P356 | DOI | 10.1586/14787210.7.2.183 |
| P698 | PubMed publication ID | 19254166 |
| P2093 | author name string | Michael W Ellis | |
| P2860 | cites work | Guidelines for the Management of Adults with Hospital-acquired, Ventilator-associated, and Healthcare-associated Pneumonia | Q22241905 |
| Silver-coated endotracheal tubes and incidence of ventilator-associated pneumonia: the NASCENT randomized trial | Q28291322 | ||
| Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America | Q29616084 | ||
| Invasive methicillin-resistant Staphylococcus aureus infections in the United States | Q29616087 | ||
| Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study | Q31918107 | ||
| Subinhibitory concentrations of linezolid reduce Staphylococcus aureus virulence factor expression | Q33197091 | ||
| Staphylococcus aureus Panton-Valentine leukocidin causes necrotizing pneumonia | Q34002030 | ||
| Efficacy of telavancin (TD-6424), a rapidly bactericidal lipoglycopeptide with multiple mechanisms of action, in a murine model of pneumonia induced by methicillin-resistant Staphylococcus aureus | Q34077052 | ||
| Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia | Q34783668 | ||
| Efficacy of linezolid alone or in combination with vancomycin for treatment of experimental endocarditis due to methicillin-resistant Staphylococcus aureus | Q35685049 | ||
| Analysis of vancomycin entry into pulmonary lining fluid by bronchoalveolar lavage in critically ill patients | Q35808723 | ||
| Subglottic secretion drainage for preventing ventilator-associated pneumonia: a meta-analysis. | Q36003443 | ||
| The pharmacokinetic and pharmacodynamic properties of vancomycin | Q36328971 | ||
| The role of vancomycin in the treatment paradigm | Q36328981 | ||
| Early microbiological response to linezolid vs vancomycin in ventilator-associated pneumonia due to methicillin-resistant Staphylococcus aureus | Q38387768 | ||
| Telavancin penetration into human epithelial lining fluid determined by population pharmacokinetic modeling and Monte Carlo simulation | Q39686295 | ||
| In vitro bactericidal activities of linezolid in combination with vancomycin, gentamicin, ciprofloxacin, fusidic acid, and rifampin against Staphylococcus aureus | Q39730651 | ||
| Predictors of mortality for methicillin-resistant Staphylococcus aureus health-care-associated pneumonia: specific evaluation of vancomycin pharmacokinetic indices | Q39771366 | ||
| Continuation of a randomized, double-blind, multicenter study of linezolid versus vancomycin in the treatment of patients with nosocomial pneumonia | Q43781411 | ||
| Methicillin-resistant Staphylococcus aureus prolongs intensive care unit stay in ventilator-associated pneumonia, despite initially appropriate antibiotic therapy | Q43905496 | ||
| In vitro activity of linezolid alone and in combination with gentamicin, vancomycin or rifampicin against methicillin-resistant Staphylococcus aureus by time-kill curve methods | Q44374440 | ||
| Comparison of community- and health care-associated methicillin-resistant Staphylococcus aureus infection | Q44686515 | ||
| Clinical cure and survival in Gram-positive ventilator-associated pneumonia: retrospective analysis of two double-blind studies comparing linezolid with vancomycin | Q44721295 | ||
| Ventilator-associated pneumonia patients who do not reduce bacteria from the lungs have a worse prognosis | Q44808648 | ||
| Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections | Q45127594 | ||
| Severe community-onset pneumonia in healthy adults caused by methicillin-resistant Staphylococcus aureus carrying the Panton-Valentine leukocidin genes | Q45198281 | ||
| High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity | Q45302930 | ||
| Decontamination of the digestive tract and oropharynx in ICU patients | Q46178068 | ||
| Pharmacokinetics and intrapulmonary concentrations of linezolid administered to critically ill patients with ventilator-associated pneumonia | Q46589068 | ||
| Are community-associated methicillin-resistant Staphylococcus aureus (MRSA) strains replacing traditional nosocomial MRSA strains? | Q46759948 | ||
| Pleuropulmonary complications of Panton-Valentine leukocidin-positive community-acquired methicillin-resistant Staphylococcus aureus: importance of treatment with antimicrobials inhibiting exotoxin production | Q46763901 | ||
| Hyperlactacidemia potentially due to linezolid overexposure in a liver transplant recipient | Q46878735 | ||
| Efficacy of telavancin in a murine model of pneumonia induced by methicillin-susceptible Staphylococcus aureus | Q46907214 | ||
| Monitoring of vancomycin serum levels for the treatment of staphylococcal infections | Q46929797 | ||
| Microbiology of ventilator-associated pneumonia compared with that of hospital-acquired pneumonia. | Q50981341 | ||
| Clinical characteristics and treatment patterns among patients with ventilator-associated pneumonia. | Q51206353 | ||
| P433 | issue | 2 | |
| P921 | main subject | linezolid | Q411377 |
| ventilator | Q813243 | ||
| P304 | page(s) | 183-188 | |
| P577 | publication date | 2009-03-01 | |
| P1433 | published in | Expert Review of Anti-infective Therapy | Q15734432 |
| P1476 | title | Affect of linezolid in ventilator-associated pneumonia caused by MRSA. | |
| P478 | volume | 7 |
Search more.